Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fluconazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioavailability of Flucanazole
Details : Fluconazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Candidiasis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 06, 2020
Lead Product(s) : Fluconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nitisinone
Therapeutic Area : Genetic Disease
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bio Equivalency 20 Mgm Orfadin and 20 Mgm of Nitisonine
Details : Nitisinone is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Tyrosinemias.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 03, 2019
Lead Product(s) : Nitisinone
Therapeutic Area : Genetic Disease
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tobramycin
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tobramycin is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Blepharo Conjunctivitis.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
June 05, 2019
Lead Product(s) : Tobramycin
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Bharath Charitable Cancer Hospital and Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
To Study the Concentration Level of, Doxil, and Doxorubicin at Various Time Frames
Details : Doxorubicin is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
June 05, 2019
Lead Product(s) : Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Bharath Charitable Cancer Hospital and Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
